Introduction
Angiogenesis represents an essential step in tumor proliferation, expansion and metastasis (1) . It is generally accepted that there are two stages of tumor progression regarding its vasculature (2, 3) . During the initial avascular stage of tumor growth (tumor mass , 0.5 mm), nutrition and oxygen delivery can be achieved by diffusion. When tumor mass grows .0.5 mm, nutrition through diffusion is no longer sufficient and formation of new vasculature is necessary for further growth (vascular stage) (4, 5) . The tumor remains in a dormant state until it can stimulate blood vessel growth from nearby pre-existing capillaries, a process known as angiogenesis. First, the formation of functional blood vessels involves a series of coordinated biological processes such as cell proliferation, guided migration, differentiation and cellcell communication (6) . Moreover, the production, by endothelial cells, of angiogenic factors such as vascular endothelial growth factor (VEGF), metalloproteinases 2 (MMP2), nitric oxide (NO) and superoxide anion (O À 2 ) plays a key role in angiogenesis (7) . Anti-angiogenic agents are now considered as an important cancer therapy option.
Eukaryotic DNA topoisomerase I (Top I) efficiently relaxes DNA supercoils during basic cellular processes such as DNA replication, transcription, recombination, repair and chromatin remodeling (8) . Consistent with the role of Top I in promoting cell growth, Top I enzyme activity and/or levels are elevated in several types of cancers (9) . Top I is recognized as the specific target of camptothecin, a commonly used inhibitor of Top I in cancer therapy (10) . Other Top I inhibitors (e.g. indolocarbazoles, phenanthridines and indenoisoquinolines) have also been described (11) . Among these molecules, fagaronine derivatives such as ethoxidine, a camptothecin analogue, and its metabolites (ethoxy-fagaronine) have been synthesized by our group (12) ; these latter agents have been shown to inhibit the cell growth of different cell lines including the human leukemia, L1210, and a number of those from solid tumors (HT-29, A-549, MCF-7 and CaOv3 cells) (11, 13) . Although ethoxidine inhibits the proliferation of various tumor cell lines (11) , no study has, to date, focused on the influence of this molecule in the regulation of angiogenesis.
Top I is highly expressed in endothelial cells (14, 15) and several studies have focused on the role of Top I inhibitors in the regulation of angiogenic steps. For example, previous studies documented that the Top I inhibitor topotecan inhibits angiogenic growth in the in vivo rat disc angiogenesis model (16) . Similar results have also been reported in a mouse cornea angiogenesis model in vivo (17) . Furthermore, Top I inhibition decreases VEGF expression in a model of neuroblastoma (18) . Interestingly, inhibition of Top I regulates differential endothelial NO synthase (eNOS) expression in human umbilical vein endothelial cells (HUVECs) (19) suggesting its involvement in the regulation of endothelial function.
The anti-proliferative properties of several Top I inhibitors (camphothericin, irinotecan) including ethoxidine have been tested using a wide range of concentration from 10 À9 to 10 À5 M (11, 13, 20, 21) . Beside, ethoxidine has been reported to be 10-fold greater more potent in inhibiting Top I on K562 and A549 cancer cell lines, compared with other inhibitors. However, the effects of these concentrations of ethoxidine on angiogenesis are not known. Since the bioavailability of this compound is not completely known, we have chosen to test its effects on in vitro angiogenesis in two types of human endothelial cells (i.e. EaHy.926 cell line and HUVECs), using two concentrations of ethoxidine. For this purpose, low (10 À9 M) and high (10 À5 M) concentrations of ethoxidine were tested on cell migration, proliferation, adhesion and formation of capillary-like structures.
Materials and methods
Material Ethoxidine was synthesized as described previously (11) and was dissolved in sterile water. Trypsin ethylenediaminetetraacetic acid and culture 'media' were obtained from Lonza (Basel, Switzerland). VEGF was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture
The EaHy.926 (American Type Culture Collection, Manassas, VA,) endothelial cell line was maintained at 37°C in a humidified incubator gassed with 5% CO 2 in air and was cultured in growth medium (Dulbecco's modified Eagle's medium:-Ham's F-12, 1:1; Lonza) supplemented with 1% L-glutamine, 1% non-essential amino acids, 1% Na-pyruvate, 1% streptomycin/penicillin (Lonza), 1% hypoxanthine, aminopterin, thymidine (Sigma-Aldrich, St Louis, MO) and 10% of heatinactivated fetal bovine serum (FBS) (Invitrogen, Cergy Pontoise, France).
Also, freshly delivered umbilical cords were obtained from a nearby hospital. HUVECs were obtained as described previously (22) and grown on plastic flasks in MCDB 131 medium (Invitrogen) containing 1% L-glutamine, 1% streptomycin/penicillin, 500 ng/l epidermal growth factor, 1 lg/l basic fibroblast growth factor, supplemented with 10% of heat-inactivated FBS. HUVECs were used at the second to fourth passage. Cells were grown for 24 h in the absence or presence of 10 À9 or 10 À5 M ethoxidine or VEGF (20 ng/ml).
In vitro capillary network formation on ECM gelÒ
After 24 h of incubation with ethoxidine or VEGF (20 ng/ml), HUVECs and EaHy.926 cells were detached with trypsin ethylenediaminetetraacetic acid. Cells were seeded with a density of 150 Â 10 3 cells per well precoated with ECM gelÒ (Sigma-Aldrich). Briefly, 150 ll of ECM gelÒ substrate diluted with FBS-free medium (1:1 dilution) was added into a four-well plate and allowed to solidify for 1 h at 37°C. Then, cells were incubated with medium containing 10% of FBS and allowed to adhere for 1 h after which the different 'stimuli' were added. To determine pro-or anti-angiogenic properties of ethoxidine, cells were cultured either with 10 À9 or 10 À5 M ethoxidine for 24 h in media completed or not with 10% of heat-inactivated FBS. Tube formation was examined by phase-contrast microscopy (MOTIC AE21) after 4 and 24 h and was quantified using ImageJ software.
Adhesion assay on EaHy.926 cells or HUVECs Evaluation of adherent cells was performed using crystal violet staining. For adhesion experiments, 5 Â 10 3 cells per well were seeded into 96-well plates for 24 h before addition of ethoxidine (10 À9 and 10 À5 M). After 24 h of incubation, the plate was shacked for 15 s. The supernatant with non-adherent cells was removed by three washes with washing buffer (0.1% bovine serum albumin in medium without serum). Attached cells were fixed with 4% of paraformaldehyde for 15 min at room temperature. Cells were rinsed two times with washing buffer, stained with crystal violet (Sigma-Aldrich) (1 mg/ml in À9 or 10 À5 M ethoxidine for 24 h. VEGF (20 ng/ml) was used as positive control. Capillary length was used to quantify angiogenesis. Reproducible data were obtained from three independent experiments. ÃÃ P , 0.01 versus NaCl. (C) HUVECs were cultured in medium supplemented with 10% FBS. VEGF (20 ng/ml) was used as positive control. Capillary length was used to quantify angiogenesis. Reproducible data were obtained from three independent experiments; Ã P , 0.05 versus NaCl; ÃÃÃ P , 0.001 versus NaCl. Apoptosis measurement by flow cytometry EaHy.926 were exposed to 10 À5 M ethoxidine for 24 h and then fixed in 70% ethanol at 4°C for 4 h. After a centrifugation at 15 000g for 5 min, cells were resuspended in PBS containing 0.05 mg/ml RNase (Sigma-Aldrich) and 10 lg/ml propidium iodide (Sigma-Aldrich). Cellular DNA content was analyzed on a Cytomics FC500 MPL flow cytometer (Beckman Coulter, Villepinte, France). In all cases, at least 10 000 events were collected for analysis.
Migration assay
Evaluation of EaHy.926 cell migration was performed using OrisÒ cell migration assembly kit-flex (Platypus Technologies, Madison, WI) according to manufacturer's instructions. Briefly, OrisÒ cell seeding stoppers were inserted into 96-well plates to create a detection zone. Then, when cells were confluent, the stoppers were removed and cells were treated with ethoxidine (10 À9 and 10 À5 M) or VEGF (20 ng/ml) for 48 h. Finally, cell migration was assessed using an inverted microscope (MOTIC AE21).
Gelatin zymography
Equal amounts of conditioned media (10 lg) were analyzed by gelatin zymography under non-reducing conditions using a 10% (vol/vol) polyacrylamide gel containing 1 mg/ml gelatin. After electrophoresis, gels were washed twice in 50 mM Tris-HCl pH 7.5, 5 mM CaCl 2 and 2.5% (vol/vol) Triton X-100 for 30 min each wash and then incubated in 50 mM Tris-HCl pH 7.5, 5 mM CaCl 2 at 37°C overnight. Gels were stained with 0.25% (wt/vol) Coomassie Brilliant Blue (G-250) dye in 10% (vol/vol) acetic acid and 10% (vol/vol) ethanol and then destained in 10% (vol/vol) acetic acid and 10% (vol/vol) ethanol until clear bands of MMP2 were visualized. 
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Western blot
After treatment, cells were homogenized and lysed. Proteins (30 lg) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Blots were probed with peNOS-Ser, peNOS-Thr, phospho-p42/p44, p42/p44, pAkt, Akt (Cell Signaling, Beverly, MA), eNOS (BD Biosciences, San Jose, CA) and VEGF antibodies (Santa Cruz Biotechnology). Monoclonal antib-actin antibody (Sigma-Aldrich) was used to visualize protein gel loading. The membranes were then incubated with the appropriate horseradish peroxidaseconjugated secondary antibody (Amersham Biosciences, Piscataway, NJ). The protein-antibody complexes were detected by Enhanced chemiluminescence plus (Amersham Biosciences).
Quantitative real-time reverse transcription-polymerase chain reaction analysis EaHy.926 cells were grown for 24 h in the presence or absence of ethoxidine (10 À9 and 10 À5 M) or VEGF (20 ng/ml). Cells were detached using trypsin and after two subsequent steps of centrifugation at 500g for 10 min, the pellet containing cells were frozen in liquid N 2 and used to investigate the expression of messenger RNA (mRNA) for eNOS, VEGF and MMP2 transcripts by realtime reverse transcription-polymerase chain reaction (PCR). Reverse transcription-PCR analyses were carried out by Service Commun de Cytométrie et d'Analyses Nucléotidiques from Angers University on Chromo 4TM (BioRad, Hercules, CA) using the SYBR Green PCR Master Mix (Invitrogen). The PCR consisted of 7.5 ll of SYBR Green PCR Master Mix, 10 nM of forward and reverse primers and 2.0 ll of 1:20-diluted template complementary DNA in a total volume of 20 ll. Cycling was performed using the conditions 10 min at 95°C, followed by 40 rounds of 15 s at 95°C and 1 min at 60°C. To verify that the used primer pair produced only a single product, a dissociation protocol was added after thermocycling, determining dissociation of the PCR products from 65°C to 95°C. We selected the HPRT gene as an endogenous control. Finally, the quantification of mRNA was performed according to the DCt method.
Statistical analysis
Data are represented as mean ± SEM, n represents the number of experiments repeated at least in triplicate. Statistical analyses were performed by analysis of variance followed by a Bonferroni test. P , 0.05 was considered to be statistically significant.
Results
Low concentration of ethoxidine promotes in vitro angiogenesis and high concentration decreased it
To determine the pro-and anti-angiogenic properties of ethoxidine, EaHy.926 ( Figure 1A ) and HUVECs ( Figure 1B and C) were treated with 10 À9 or 10 À5 M ethoxidine in a medium with or without 10% FBS.
As shown in Figure 1A , EaHy.926 endothelial cells failed to organize in capillary-like structures in medium supplemented with 10% FBS. After 24 h of treatment with 10 À9 M ethoxidine, EaHy.926 reorganized and formed capillaries on ECM gelÒ. In contrast, 10 À5 M ethoxidine was not able to promote the organization and the formation of capillaries. As control, VEGF (20 ng/ml) increased the formation of capillaries. Likewise, under basal conditions in the absence of FBS, EaHy.926 cells failed to organize in capillary-like structures, whereas treatment with 10 À9 M ethoxidine promoted the formation of capillaries and 10 À5 M inhibited their formation (data not shown). HUVECs failed to organize in capillary-like structures in basal conditions, without FBS ( Figure 1B) . After 24 h of treatment with 10 À9 M ethoxidine, HUVECs formed capillaries, whereas 10 À5 M had no effect. The summary of capillary length measurements confirmed the differential effects of ethoxidine at the two concentrations used ( Figure 1B) . Although in the absence of treatment, HUVECs were able to form capillaries, in medium supplemented with 10% FBS, 10 À9 M ethoxidine enhanced capillary-like structure formation as illustrated by the capillary length measurement, whereas 10 À5 M ethoxidine completely inhibited this process ( Figure 1C ). As control, VEGF (20 ng/ml) favored the formation of capillaries. These data strongly suggest ethoxidine posses either pro-or anti-angiogenic properties depending on the concentrations used.
Ethoxidine does not affect endothelial cell adhesion Neither a low (10 À9 M) or high (10 À5 M) concentration of ethoxidine had an effect on the adhesion of EaHy.926 (Figure 2A) or HUVEC ( Figure 2B ) cells, as determined with the adhesion assay using crystal violet. However, VEGF (20 ng/ml, for 24 h) increased cell adhesion under similar experimental conditions.
Ethoxidine modulates both endothelial cell proliferation and migration Because endothelial cell proliferation represents a critical step in angiogenesis, we investigated the effect of ethoxidine on this cellular Paradoxical effects of ethoxidine process. We highlighted proliferative properties for ethoxidine at low concentration. Indeed, 10 À9 M ethoxidine was able to increase significantly EaHy.926 ( Figure 3A) and HUVECs ( Figure 3B ) proliferation. In contrast, high concentration of ethoxidine reduced proliferation of both EaHy.926 ( Figure 3A) and HUVECs ( Figure 3B ). As expected, VEGF treatment induced an increase of endothelial cell proliferation in the two endothelial cell types studied.
Since similar effects of ethoxidine were obtained in the two endothelial cell types, we have chosen to use only EaHy.926 in the following experiments. Thus, to ensure the absence of cytotoxicity and apoptosis of 10 À5 M ethoxidine on EaHy.926 cells, viability and apoptosis measurements were performed by MTT assay and DNA hypodiploid quantification by flow cytometry, respectively. No cytotoxic effect was observed in cells treated by high concentration of ethoxidine ( Figure 3C ). Analysis of apoptosis by flow cytometry showed no effect of high concentration ethoxidine. As expected, actinomycin D treatment increased the apoptosis of EaHy.926 cells ( Figure 3D ).
As migration of endothelial cells contributes to angiogenesis by dissemination from the pre-existing vessel to form new vessels, we studied the effects of ethoxidine on endothelial cell migration on EaHy.926 cell line. We observed that low concentration of ethoxidine increased endothelial cell migration to a similar extent to that observed with VEGF. Conversely, treatment with high concentration of ethoxidine decreased cell migration ( Figure 4A ). These results were confirmed by the migration area measurement ( Figure 4B ). Since metalloproteinases, including MMP2, control cell migration, its expression and activity were evaluated in EaHy.926 cell lines. Both MMP2 mRNA expression ( Figure 4C ) and activity ( Figure 4D ) were enhanced after treatment of EaHy.926 cell line with 10 À9 M ethoxidine. In contrast, 10 À5 M ethoxidine reduced both the expression ( Figure 4C ) and the activity ( Figure 4D ) of MMP2 under the same experimental conditions. As positive control, VEGF increased migration, MMP2 expression and activity in EaHy.926 cell line.
Ethoxidine regulates NO release in endothelial cells by modulating eNOS activity Treatment of EaHy.926 cells with ethoxidine (10 À9 M) significantly increased NO production ( Figure 5A ), whereas high concentration of ethoxidine (10 À5 M) was without effect on release of NO as measured by the EPR method using Fe(DETC) 2 . To determine the molecular changes governing the reduction of NO release induced by ethoxidine in endothelial cells, we analyzed expression and activation of enzymes linked to NO pathway by real-time reverse transcription-PCR and western blotting. An increase in eNOS mRNA was observed in cells treated with 10 À9 M ethoxidine, whereas 10 À5 M ethoxidine decreased its expression ( Figure 5B ). Western blot analysis revealed that 10 À9 M ethoxidine did not modify eNOS expression, whereas 10 À5 M ethoxidine decreased it. Furthermore, 10 À9 M ethoxidine enhanced eNOS phosphorylation on its activator site (Ser-1177) but did not modify its phosphorylation at the inhibitor (Thr-495) site. Conversely, 10 À5 M ethoxidine decreased eNOS phosphorylation on its activator site and enhanced its phosphorylation at the inhibitor site ( Figure 5C ). In addition, after normalization of the amount of phosphorylated eNOS to total amount of the enzyme, the ratio of phosphorylated eNOS at the activator and inhibitor sites was calculated. Interestingly, this ratio was greater in cells treated with 10 À9 M ethoxidine and was lower in cells treated with 10 À5 M ethoxidine compared with control cells ( Figure 5D ). As positive control, VEGF increased eNOS and p-eNOS-Ser-1177 and decreased p-eNOS-Thr-495 expressions in EaHy.926 endothelial cells although the ratio of phosphorylation was not statistically different. Because the activation of extracellular signal-regulated kinase (ERK) 1/2 is an important signaling event for endothelial angiogenic processes, we determined whether ethoxidine modulates the phosphorylation of ERK1/2 in EaHy.926 endothelial cells. Treatment of EaHy.926 endothelial cells with 10 À9 M ethoxidine increased both ERK1/2 expression and its phosphorylation like VEGF, whereas 10 À5 M ethoxidine was without effect compared with untreated cells (Figure 5E ).
It has been well known that the activation of Akt directly phosphorylates eNOS at its activator site Ser-1177 and subsequently increases NO production. Interestingly, low concentration of ethoxidine did not alter Akt expression but stimulated its phosphorylation. High concentration of ethoxidine did not affect both Akt expression and phosphorylation ( Figure 5F ). Figure 6A ) but had no effect on its protein expression ( Figure 6B and C) under the same experimental condition.
Discussion
The present study provides evidence that depending on the concentration, ethoxidine regulates the steps involved in angiogenesis. Thus, low concentration ethoxidine (10 À9 M) increased capillary-like formation through the increase of cell proliferation and migration. These effects were associated with enhanced O À 2 and NO productions and upregulation of VEGF expression. Conversely, high concentration ethoxidine (10 À5 M) inhibited in vitro angiogenesis decreasing endothelial cell proliferation and migration but it modified neither VEGF expression nor NO or O À 2 productions. Taken together, these data highlight the paradoxical effects of ethoxidine on key cellular processes involved on angiogenesis. Although the link between inhibition of Top I and angiogenic properties of ethoxidine has not been tested, the present study highlights the paradoxical effects of this inhibitor on key cellular processes involved on angiogenesis. A schematic of mechanisms of ethoxidine on angiogenesis process is illustrated on Figure 7 .
The anti-proliferative properties of several Top I inhibitors (camptothecin, irinotecan) has been first studied on different tumor cell model (20, 21) using concentrations ranged between 10 À9 to 10 À5 M. Among these drugs, it was shown that ethoxidine has a 10-fold greater potency on Top I inhibition in K562 and A549 cancer cell lines, as compared with other inhibitors (24) . These effects on tumor cell proliferation were observed also with concentrations ranged between 10 À9 to 10 À5 M (11). Recently, similar concentrations were tested with ethoxy-fagaronine, one of the metabolites of ethoxidine, and an inhibition of L1210 leukemia cell proliferation was reported with maximal effective concentration 10 À7 M (13). Since the bioavailability of this compound is not completely known, we have chosen to test its effects on in vitro angiogenesis in two types of human endothelial cells (i.e. EaHy.926 cell line and HUVECs), using ethoxidine at low and high concentrations. Although we reported paradoxical effects of ethoxidine on in vitro angiogenesis, it might be useful to clarify the bioavailability of this compound to determine the doses necessary to inhibit tumor growth, first in mice and then in human.
Angiogenesis is critical for tumor development (25) and neovascularization is now known as a pre-requisite to the rapid expansion of tumor cells associated with formation of macroscopic tumors (26) . The ability of endothelial cells to form capillary tubes is a specialized function of this cell type resulting from a finely tuned balance between cell migration, proliferation and adhesion (27) . The two concentrations of ethoxidine do not induce either cytotoxicity or apoptosis. Interestingly, 10 À9 M ethoxidine had pro-angiogenic properties as shown by its ability to induce formation of capillary tubes both in EaHy.926 and HUVECs grown in both serum-deprived and complete media. Conversely, 10 À5 M ethoxidine possessed anti-angiogenic properties in as much it strongly reduced capillary-like structures formation in EaHy.926 and HUVECs grown under the same experimental conditions. These results highlighted different properties of ethoxidine on in vitro angiogenesis depending on the concentrations used. Unlike the present work, previous in vitro and in vivo studies have reported that high concentrations of topotecan (5 Â 10 À8 to 2 Â 10 À7 M), another Top I inhibitor, had anti-angiogenic effects in MatrigelÒ migration assay and in morphogenesis assay (16, 28) . These two studies have been conducted with high concentrations known for their antitumor properties. The present study highlights paradoxical effects of ethoxidine on angiogenesis using two different concentrations.
The analysis of cellular processes involved on in vitro angiogenesis revealed that both cell proliferation and migration were enhanced by 10 À9 M ethoxidine, whereas these cellular processes were inhibited by 10 À5 M ethoxidine. In addition, ethoxidine was able to modulate MMP2 expression and activity according to the concentrations used. These results suggest that ethoxidine is able to differentially regulate events leading to angiogenesis. Similar results have been reported with topotecan, which mediates activation of transcription factors that regulate MMP2 expression both in tumor cells (29) and in endothelial cells (30) suggesting that it affects both tumor cells and endothelial cells for its therapeutic property when it is used at high concentration (10 À7 to 10 À6 M). Also, it is clear from the present study that ethoxidine at a concentration at which it had no reported effect on tumor cells (i.e. 10 À9 M), it stimulates the processes leading to angiogenesis and therefore might be harmful when it is intended to treat cancers.
Beside its capacity to regulate permeability and blood flow, NO has been reported to be essential in cellular processes leading to angiogenesis (31) and to exert angiogenic properties in various tumor models (for review, see ref. 32 ). Low concentration (10 À9 M) ethoxidine significantly enhanced NO production, whereas no variation was found in cells treated with high concentration (10 À5 M) ethoxidine, in the present study. Moreover, low concentration ethoxidine increased eNOS mRNA expression and potentiated eNOS phosphorylation on its activator site, whereas high concentration decreased eNOS mRNA expression and favored eNOS phosphorylation on its inhibitor site. In HUVECs model, it was reported that NO production was mediated by phosphorylation of eNOS on its activator site (Ser-1177) and then activation of Akt (33) . Interestingly, phosphorylation of Akt was greater in EaHy.926 cells treated with low concentration ethoxidine than in cells treated with high concentration. The serine/ threonine protein kinase Akt is a downstream effector of Phosphoinositide-3-kinase that is activated by a variety of growth factors including those known to induce angiogenesis, such as VEGF and basic fibroblast growth factor in endothelial cells (34, 35) , suggesting a possible involvement of the PI3K-Akt pathway in the angiogenic process (36) . If the link between DNA Top I and PI3K/Akt is not clear, the present study showed that inhibition of Top I activity with ethoxidine was associated with a decreased activity of Akt as reported by Nakashio et al. (30) with topotecan. In this last study, the authors claim that 10 À7 M topotecan inhibits VEGF expression via a downregulation of the PI3K/Akt pathway.
In tumor-associated angiogenesis, angiogenic factors secreted by endothelial and tumor cells stimulate the growth of solid tumors (37) . Among these factors, VEGF represents the major player in angiogenesis initiation by inducing endothelial NO production (38) . Here, the analysis of VEGF expression revealed that 10 À9 M ethoxidine enhanced mRNA expression, whereas 10 À5 M ethoxidine inhibited it. Because mRNA transcription and protein synthesis are not simultaneous, we studied VEGF protein expression after a treatment with ethoxidine for 36 h. In these conditions, the results observed by western blot confirmed those obtained by quantitative reverse transcription-PCR. As VEGF regulates endothelial cell proliferation and migration using mitogen-activated protein kinase-dependent pathways (39) , the phosphorylation of ERK1/2 has been evaluated. Low concentration of ethoxidine led to an increase of ERK1/2 phosphorylation greater than that observed for high concentration. The findings of this study suggest that paradoxical properties of ethoxidine on in vitro angiogenesis could be mediated by VEGF, which regulates the activity of ERK1/2 and whose expression is controlled by ethoxidine. As such, as for other molecules such as sorafenib (40) , high concentration ethoxidine might be of interest in the treatment of tumor angiogenesis.
With regard to ROS production, 10 À9 M ethoxidine was able to increase O À 2 production, whereas no change in O À 2 production was observed with 10 À5 M. The modulation of O À 2 production by ethoxidine could explain the paradoxical properties of this molecule in the regulation of angiogenesis, particularly for low concentration ethoxidine. It was reported that ROS production stimulates induction of VEGF in various cell types (41) and promotes cell proliferation and migration (23) , cytoskeletal reorganization (42) and tubular morphogenesis (43) in endothelial cells. Thus, the present study showed that low concentration ethoxidine induced an increase of O À 2 production associated with overexpression of VEGF and MMP2, which could explain its pro-angiogenic property. However, it is important to note that overproduction of ROS could be deleterious for Top I structure in endothelial cells. Indeed, recently, it was shown that ROS overproduction by endothelial cells could induce an oxidation of DNA Top I leading to the formation of oxidized DNA Top I that plays a direct pathogenic role in systemic sclerosis (44) . À9 M) ethoxidine increases cell migration and proliferation by enhancing MMP2 expression and activity and the phosphorylation of ERK1/2, respectively. Moreover, low concentration of ethoxidine induces an overexpression of VEGF and NO through an increase of eNOS phosphorylation on its activator site (Ser-1177). These observations confirm the pro-angiogenic properties of low concentration ethoxidine. On another hand, high concentration (10 À5 M) ethoxidine exerts anti-angiogenic properties by decreasing endothelial cell migration and proliferation through a reduction of MMP2 expression and activity and a decrease of the phosphorylation of ERK1/2, respectively. Finally, treatment with 10 À5 M ethoxidine decreases eNOS expression and favors its phosphorylation on its inhibitor site (Thr-495). pERK, phosphorylated extracellular signal-regulated kinases; p-eNOS-Ser, endothelial nitric oxide synthase phosphorylated on serine residue; p-eNOS-Thr, endothelial nitric oxide synthase phosphorylated on threonine residue.
Paradoxical effects of ethoxidine
The main finding of the present study is the demonstration of paradoxical properties of a potent Top I inhibitor, ethoxidine in the regulation of in vitro angiogenesis. Although components of angiogenesis such as endothelial cell proliferation, migration and tube formation in vitro do not always correlate with angiogenesis in vivo, preliminary studies indicated that low dose of ethoxidine enhanced post-ischemic revascularization (SF, unpublished results). We can advance the hypothesis of a dual therapeutic benefit or deleterious depending on the concentrations used. First, ethoxidine at high concentrations could be used as anticancer drug targeting both tumor growth and metastasis by inhibiting angiogenesis. These properties confirmed those highlighted with other Top I inhibitors such as topotecan showing simultaneously anti-proliferative and anti-angiogenic properties on different cell models (45, 46) . A second finding of the present study provides a rational explanation for the probable beneficial effects of low dose of ethoxidine against ischemic diseases, although no study had yet clearly demonstrated their pro-angiogenic effect in ischemic conditions, especially in vivo. These data suggest a new therapeutic approach involving ethoxidine, a Top I inhibitor, to promote or inhibit angiogenesis depending on the concentrations used.
Funding
Institut National de la Santé et de la Recherche Médicale; Université d'Angers.
